XBiotech is a biotechnology business based in the US. XBiotech stocks (XBIT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.45 – a decrease of 3.42% over the previous week. XBiotech employs 97 staff and has a trailing 12-month revenue of around $14 million.
Finder's Pick for
Beginners
Finder's Pick for
Global Trading
Finder's Pick for
Free Trades
| Latest market close | $5.08 |
|---|---|
| 52-week range | $4.87 - $16.50 |
| 50-day moving average | $5.52 |
| 200-day moving average | $9.19 |
| Wall St. target price | $18.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.67 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $5.08 from 2022-08-11
| 1 week (2022-08-05) | -3.42% |
|---|---|
| 1 month (2022-07-13) | -4.51% |
| 3 months (2022-05-09) | -20.13% |
| 6 months (2022-02-09) | N/A |
| 1 year (2021-08-13) | -71.73% |
|---|---|
| 2 years (2020-08-13) | -70.14% |
| 3 years (2019-08-13) | 7.4 |
| 5 years (2017-08-11) | 11.89% |
| Revenue TTM | $14 million |
|---|---|
| Gross profit TTM | $12.6 million |
| Return on assets TTM | -5.86% |
| Return on equity TTM | -6.55% |
| Profit margin | -144.13% |
| Book value | $8.72 |
| Market capitalisation | $160.1 million |
TTM: trailing 12 months
We're not expecting XBiotech to pay a dividend over the next 12 months.
Over the last 12 months, XBiotech's shares have ranged in value from as little as $4.87 up to $16.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XBiotech's is 1.3338. This would suggest that XBiotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
XBiotech Inc. , a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas. .
You can’t buy NFL stock directly, but you can invest in companies that back the football industry.
Read more…
Compare 15 of the best stock picking services, and learn how to choose the best option for your needs.
Read more…
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…Everything we know about the GigaCloud Technology Inc. IPO plus information on how to buy in.
Everything we know about the Starbox Group Holdings Ltd. IPO plus information on how to buy in.
Steps to owning and managing MEGL stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing QS stock, with 24-hour and historical pricing before you buy.
Everything we know about the Bruush Oral Care IPO plus information on how to buy in.
Everything we know about the Loop Media IPO plus information on how to buy in.
Are you looking to start stock trading? Here’s our top 7 tips to help you begin.
Everything we know about the Savage X Fenty IPO plus information on how to buy in.
Find out the key differences between the FTSE 100 and the S&P 500.
Everything we know about the DeLorean Motor Company IPO plus information on how to buy in.
